• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于植物源疫苗在抗击埃博拉病毒方面发展的展望

A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus.

作者信息

Rosales-Mendoza Sergio, Nieto-Gómez Ricardo, Angulo Carlos

机构信息

Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí , San Luis Potosí, San Luis Potosí , Mexico.

Grupo de Inmunología & Vacunología, Centro de Investigaciones Biológicas del Noroeste, SC. , La Paz, Baja California Sur , Mexico.

出版信息

Front Immunol. 2017 Mar 10;8:252. doi: 10.3389/fimmu.2017.00252. eCollection 2017.

DOI:10.3389/fimmu.2017.00252
PMID:28344580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5344899/
Abstract

The Ebola virus (EBOV) epidemic indicated a great need for prophylactic and therapeutic strategies. The use of plants for the production of biopharmaceuticals is a concept being adopted by the pharmaceutical industry, with an enzyme for human use currently commercialized since 2012 and some plant-based vaccines close to being commercialized. Although plant-based antibodies against EBOV are under clinical evaluation, the development of plant-based vaccines against EBOV essentially remains an unexplored area. The current technologies for the production of plant-based vaccines include stable nuclear expression, transient expression mediated by viral vectors, and chloroplast expression. Specific perspectives on how these technologies can be applied for developing anti-EBOV vaccines are provided, including possibilities for the design of immunogens as well as the potential of the distinct expression modalities to produce the most relevant EBOV antigens in plants considering yields, posttranslational modifications, production time, and downstream processing.

摘要

埃博拉病毒（EBOV）疫情表明对预防和治疗策略有巨大需求。利用植物生产生物制药是制药行业正在采用的一个概念，一种供人类使用的酶自2012年起已商业化，一些基于植物的疫苗也即将商业化。尽管针对EBOV的植物源抗体正在进行临床评估，但针对EBOV的植物源疫苗开发基本上仍是一个未被探索的领域。目前生产植物源疫苗的技术包括稳定核表达、病毒载体介导的瞬时表达和叶绿体表达。本文提供了关于如何将这些技术应用于开发抗EBOV疫苗的具体观点，包括免疫原设计的可能性，以及考虑产量、翻译后修饰、生产时间和下游加工等因素，不同表达方式在植物中产生最相关EBOV抗原的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/04894728a018/fimmu-08-00252-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/100bd73265b8/fimmu-08-00252-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/8a8d65ac17d4/fimmu-08-00252-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/04894728a018/fimmu-08-00252-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/100bd73265b8/fimmu-08-00252-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/8a8d65ac17d4/fimmu-08-00252-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc07/5344899/04894728a018/fimmu-08-00252-g003.jpg

相似文献

1
A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus.关于植物源疫苗在抗击埃博拉病毒方面发展的展望
Front Immunol. 2017 Mar 10;8:252. doi: 10.3389/fimmu.2017.00252. eCollection 2017.
2
Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.埃博拉病毒病恢复期患者血浆中针对西非马科纳变异株埃博拉病毒的特异性中和反应。
Virus Res. 2016 Feb 2;213:224-229. doi: 10.1016/j.virusres.2015.12.019. Epub 2015 Dec 29.
3
Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.Matrix-M 佐剂增强了扎伊尔埃博拉/马科纳病毒糖蛋白（GP）纳米颗粒疫苗在小鼠中的抗体、细胞和保护性免疫应答。
Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033. Epub 2016 Feb 24.
4
Evaluation in nonhuman primates of vaccines against Ebola virus.在非人类灵长类动物中对埃博拉病毒疫苗进行评估。
Emerg Infect Dis. 2002 May;8(5):503-7. doi: 10.3201/eid0805.010284.
5
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.一种基于cAdVax的二价埃博拉病毒疫苗的研发，该疫苗可诱导针对苏丹型和扎伊尔型埃博拉病毒的免疫反应。
J Virol. 2006 Mar;80(6):2738-46. doi: 10.1128/JVI.80.6.2738-2746.2006.
6
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.基于埃博拉病毒样颗粒的疫苗可保护非人灵长类动物免受致命埃博拉病毒的攻击。
J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7. doi: 10.1086/520583.
7
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.用高度减毒的重组水疱性口炎病毒载体进行疫苗接种可抵御致死剂量埃博拉病毒的攻击。
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.
8
Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.在一项短期保护研究中针对小鼠适应型埃博拉病毒的初免-加强免疫接种策略的优化
J Infect Dis. 2015 Oct 1;212 Suppl 2:S389-97. doi: 10.1093/infdis/jiv175. Epub 2015 Jun 2.
9
Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.设计针对埃博拉病毒的有效水疱性口炎病毒载体疫苗。
Methods Mol Biol. 2016;1403:245-57. doi: 10.1007/978-1-4939-3387-7_12.
10
Plant-derived pharmaceuticals for the developing world.发展中国家的植物药。
Biotechnol J. 2013 Oct;8(10):1193-202. doi: 10.1002/biot.201300162. Epub 2013 Jul 15.

引用本文的文献

1
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.基于植物的新冠疫苗作为大流行防范措施出现的紧迫性。
Vaccines (Basel). 2023 Aug 9;11(8):1347. doi: 10.3390/vaccines11081347.
2
Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges.埃博拉病毒病疫苗：研发、当前观点与挑战
Vaccines (Basel). 2023 Jan 26;11(2):268. doi: 10.3390/vaccines11020268.
3
A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques.

本文引用的文献

1
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).一种重组水疱性口炎病毒载体疫苗预防埃博拉病毒病的有效性和效果：几内亚环状疫苗接种、开放标签、整群随机试验（埃博拉到此为止！）的最终结果
Lancet. 2017 Feb 4;389(10068):505-518. doi: 10.1016/S0140-6736(16)32621-6. Epub 2016 Dec 23.
2
Ebola virus vaccines: Where do we stand?埃博拉病毒疫苗：我们目前的进展如何？
Clin Immunol. 2016 Dec;173:44-49. doi: 10.1016/j.clim.2016.10.016. Epub 2016 Oct 28.
3
Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.
一种在植物中生产的重组亚单位候选疫苗可在猕猴体内引发针对新冠病毒变异株的中和抗体。
Front Plant Sci. 2022 Sep 28;13:901978. doi: 10.3389/fpls.2022.901978. eCollection 2022.
4
Energy-efficient production of vaccine protein against porcine edema disease from transgenic lettuce (Lactuca sativa L.).从转基因生菜（生菜）中高效生产针对猪水肿病的疫苗蛋白。
Sci Rep. 2022 Sep 24;12(1):15951. doi: 10.1038/s41598-022-19491-z.
5
Functional Characterization of Pembrolizumab Produced in Using a Rapid Transient Expression System.使用快速瞬时表达系统生产的帕博利珠单抗的功能特性
Front Plant Sci. 2021 Sep 9;12:736299. doi: 10.3389/fpls.2021.736299. eCollection 2021.
6
Plant-Produced Vaccines: Future Applications in Aquaculture.植物生产的疫苗：在水产养殖中的未来应用
Front Plant Sci. 2021 Aug 12;12:718775. doi: 10.3389/fpls.2021.718775. eCollection 2021.
7
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.基于蛋白质的疫苗生产平台：从经典到下一代策略。
Biomolecules. 2021 Jul 21;11(8):1072. doi: 10.3390/biom11081072.
8
Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?对抗人类病毒性疾病：植物源疫苗会是答案吗？
Vaccines (Basel). 2021 Jul 8;9(7):761. doi: 10.3390/vaccines9070761.
9
Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.植物产生的新冠病毒受体结合域在小鼠和非人类灵长类动物中引发强烈的中和反应。
Front Plant Sci. 2021 May 13;12:682953. doi: 10.3389/fpls.2021.682953. eCollection 2021.
10
Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2.植物生产的重组ACE2-Fc融合蛋白作为抗SARS-CoV-2潜在治疗剂的开发。
Front Plant Sci. 2021 Jan 7;11:604663. doi: 10.3389/fpls.2020.604663. eCollection 2020.
感染本迪布焦病毒或埃博拉病毒的雪貂概括了人类丝状病毒病的重要方面。
J Virol. 2016 Sep 29;90(20):9209-23. doi: 10.1128/JVI.01033-16. Print 2016 Oct 15.
4
The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.家雪貂（Mustela putorius furo）作为三种埃博拉病毒的致死性感染模型。
J Infect Dis. 2016 Aug 15;214(4):565-9. doi: 10.1093/infdis/jiw209. Epub 2016 May 24.
5
Ebola virus disease candidate vaccines under evaluation in clinical trials.正在临床试验中接受评估的埃博拉病毒病候选疫苗。
Expert Rev Vaccines. 2016 Sep;15(9):1101-12. doi: 10.1080/14760584.2016.1187566. Epub 2016 May 27.
6
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.新型腺病毒 26 型和改良安卡拉痘苗病毒载体埃博拉疫苗的安全性和免疫原性：一项随机临床试验。
JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218.
7
Ebola virus vaccines - reality or fiction?埃博拉病毒疫苗——现实还是虚构？
Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. doi: 10.1080/14760584.2016.1178068. Epub 2016 May 9.
8
Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.在利比里亚埃博拉疫情期间开展埃博拉病毒病疫苗临床试验：设计、流程及挑战
Clin Trials. 2016 Feb;13(1):49-56. doi: 10.1177/1740774515621037. Epub 2016 Jan 14.
9
Towards the development of an oral vaccine against porcine cysticercosis: expression of the protective HP6/TSOL18 antigen in transgenic carrots cells.迈向猪囊尾蚴病口服疫苗的研发：保护性HP6/TSOL18抗原在转基因胡萝卜细胞中的表达
Planta. 2016 Mar;243(3):675-85. doi: 10.1007/s00425-015-2431-0. Epub 2015 Nov 27.
10
Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents.植物生产的新兴和再现传染病及生物恐怖制剂候选对策。
Plant Biotechnol J. 2015 Oct;13(8):1136-59. doi: 10.1111/pbi.12475.